Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01), Zacks reports.
Eupraxia Pharmaceuticals Stock Down 2.3 %
Shares of Eupraxia Pharmaceuticals stock opened at $3.82 on Friday. The firm has a market capitalization of $136.17 million and a P/E ratio of -5.31. Eupraxia Pharmaceuticals has a 52 week low of $2.20 and a 52 week high of $4.48. The firm’s 50 day moving average is $3.49 and its two-hundred day moving average is $3.10.
Wall Street Analyst Weigh In
Separately, Craig Hallum started coverage on shares of Eupraxia Pharmaceuticals in a research note on Friday, February 21st. They issued a “buy” rating and a $12.00 price target for the company.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Featured Articles
- Five stocks we like better than Eupraxia Pharmaceuticals
- Which Wall Street Analysts are the Most Accurate?
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
